

1 **Manuscript title:**

2 **Obesity-Associated Changes in Immune Cell Dynamics During Alphavirus Infection**
3 **Revealed by Single Cell Transcriptomic Analysis**

4 Muddassar Hameed^{1,2,3,*}, Andrea R. Daamen^{4*}, Md Shakhawat Hossain^{1,2}, Sheryl Coutermarsh-
5 Ott¹, Peter E. Lipsky⁴, James Weger-Lucarelli^{1,2,¶}

6 *These authors contributed equally

7 ¹Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary
8 Medicine, Virginia Tech, Blacksburg, VA 24061, USA

9 ²Center for Zoonotic and Arthropod-borne Pathogens, Virginia Polytechnic Institute and State
10 University, Blacksburg, VA 24061, USA

11 ³Department of Pathology & Immunology, Alvin J. Siteman Cancer Center, Washington
12 University School of Medicine, St. Louis, MO 63110, USA

13 ⁴AMPEL BioSolutions LLC and the RILITE Research Institute, Charlottesville, VA, United States

14 [¶]**Corresponding author:** James Weger-Lucarelli, Ph.D., weger@vt.edu

15

16 **Highlights**

- 17 • Obesity worsens disease outcomes following arthritogenic alphavirus infection.
- 18 • Arthritogenic alphavirus infection causes significant shifts in immune cell populations in
19 the blood and footpad.
- 20 • Blood monocytes from lean mice had higher expression of interferon response genes at the
21 later stage of infection.
- 22 • Footpads in lean mice have an expanded population of F4/80^{lo} macrophages with an
23 intense interferon response gene signature before and after alphavirus infection that is not
24 found in obese mice.
- 25 • Macrophages in obese mice express lower levels of interferon response genes, have a
26 unique necroptosis signature, and higher F4/80 expression.

27


28 **Summary**

29 Obesity induces diverse changes in host immunity, resulting in worse disease outcomes following
30 infection with various pathogens, including arthritogenic alphaviruses. However, the impact of

31 obesity on the functional landscape of immune cells during arthritogenic alphavirus infection
32 remains unexplored. Here, we used single-cell RNA sequencing (scRNA-seq) to dissect the blood
33 and tissue immune responses to Mayaro virus (MAYV) infection in lean and obese mice. Footpad
34 injection of MAYV caused significant shifts in immune cell populations and induced robust
35 expression of interferon response and proinflammatory cytokine genes and related pathways in
36 both blood and tissue. In MAYV-infected lean mice, analysis of the local tissue response revealed
37 a unique macrophage subset with high expression of IFN response genes that was not found in
38 obese mice. This was associated with less severe inflammation in lean mice. These results provide
39 evidence for a unique macrophage population that may contribute to the superior capacity of lean
40 mice to control arthritogenic alphavirus infection.

41

42 Graphical abstract



43

44

45 Key words

46 Arthritogenic alphaviruses, Obesity, single-cell RNA sequencing, Mayaro virus, interferon-
47 stimulated genes, macrophages.

48

49 Introduction

50 Arthritogenic alphaviruses, including chikungunya virus (CHIKV), Mayaro virus (MAYV), and
51 Ross River virus (RRV), cause acute and chronic disease in humans¹. Acute disease is

52 characterized by fever, rash, myalgia, and arthralgia^{2,3}. Roughly 40% of infected people develop
53 chronic disease associated with debilitating symptoms of chronic arthritis/arthralgia and fatigue
54 that can last for years after infection³⁻⁵. A recent study suggested that mortality is higher than
55 previously estimated following CHIKV infection, with an average case-fatality rate of 0.8 deaths
56 per 1,000 cases in Brazil⁶. Despite their impact on human health, no approved therapeutics are
57 available to treat alphavirus-induced disease. Although the FDA recently approved a vaccine to
58 prevent chikungunya disease, its real-world effectiveness remains to be documented⁷.

59
60 Epidemiological reports have identified factors associated with severe chikungunya disease in
61 humans, including obesity⁸, which is expected to affect 50% of the United States population by
62 2030⁹ and currently impacts 13% of adults worldwide¹⁰. Consistent with this, we previously
63 showed that obese mice develop more severe disease following infection with CHIKV, MAYV,
64 or RRV¹¹; however, the mechanisms underlying the difference in disease outcomes remain
65 unexplored. Obese hosts develop a chronic, low-grade inflammation related to the ongoing release
66 of pro-inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin 6 (IL-6)¹²⁻¹⁴.
67 This results in a dysfunctional immune response to various infectious diseases¹⁵⁻¹⁷, making obese
68 hosts more susceptible to severe disease, including during infection with arthritogenic
69 alphaviruses¹¹.

70
71 Arthritogenic alphavirus disease has been associated with a dysregulated immune response, with
72 various cell types and pro-inflammatory cytokines implicated in pathogenesis^{18,19}. Inoculation of
73 mice with an arthritogenic alphavirus induces footpad swelling, myositis, and bone loss, similar to
74 the disease observed in humans²⁰⁻²³. However, there is an incomplete understanding of the immune
75 processes driving immune/inflammatory responses to these viruses. Previous efforts to understand
76 disease pathogenesis in arthritogenic alphavirus-infected mice have included transcriptomic
77 analysis, largely based on bulk RNA sequencing²⁴⁻²⁶, which offers limited insights into the
78 heterogeneity of individual cell types^{27,28}. Recently, scRNA-seq has emerged as a means of
79 assessing the contribution of individual cell types to pathogenesis²⁹⁻³² and providing valuable
80 insights into the contribution of individual immune cell types to disease processes.

81

82 Here, we carried out scRNA-seq from immune cells isolated from blood during peak viremia (2
83 days post-inoculation [dpi]) and from blood and footpads at the time of peak footpad swelling (7
84 dpi) from mock and MAYV-infected lean and obese mice. We identified large shifts in immune
85 cell populations in the blood and footpads following MAYV infection. Notably, B cells
86 dramatically decreased in the blood at 2 dpi, whereas monocytes were enriched in both lean and
87 obese mice. In the footpad, macrophage populations increased considerably. Most cell types
88 showed significant enrichment for genes in the type I and II interferon (IFN) pathways following
89 MAYV infection. We identified a unique subset of macrophages (CSF1R⁺SiglecF⁻
90 F4/80^{lo}MHCII^{high}) that predominated in the footpad both before and following MAYV infection
91 in lean mice; these cells were not identified in obese mice. This population in lean mice was
92 enriched for IFN response genes. Since serum and tissue levels of IFNs were similar in lean and
93 obese mice, the decreased expression of IFN-response genes in obese mice suggests a defect in
94 response to IFN. These results suggest a specific cellular and functional abnormality in obese mice
95 that is associated with more severe disease.

96 **Results:**

97 **Differences in clinical severity and immune cell dynamics during MAYV infection in lean** 98 **and obese hosts**

99 To profile the host immune response to arthritogenic alphavirus infection, we infected lean and
100 obese mice with MAYV in the footpad. MAYV is a BSL2 virus and causes similar disease in
101 humans and mice as CHIKV, which requires stricter BSL3 containment. As we previously
102 demonstrated¹¹, MAYV infection caused more weight loss in obese mice compared to lean
103 controls (Figure 1A). MAYV infection also caused greater footpad swelling in obese mice
104 compared to lean mice (Figure 1B), which was associated with pronounced inflammatory cell
105 infiltration and skeletal muscle and soft tissue inflammation (Figure 1C). Finally, we observed
106 significantly greater inflammation and composite footpad pathology scores for obese mice
107 compared to the lean group (Figure 1D). These results confirm that obese mice develop more
108 severe disease following MAYV infection than lean mice.

109 We also assessed the levels of key cytokines and inflammatory markers involved in viral
110 response in the blood of lean and obese mice pre-infection and at 2 dpi (Figure 1E, S1). Expression
111 of CXCL10, IL-6, TNF, and IFNG was increased with infection in both lean and obese mice,


112 whereas expression of IL-1ra was only increased in lean-infected mice, and expression of soluble
113 LDL-R (sLDL-R) was only increased in obese infected mice (Figure 1E). Notably, only expression
114 of sLDL-R significantly increased in infected obese mice compared to lean mice.

115

116 Next, we carried out flow cytometric analysis on blood immune cells collected at pre-infection, 2
117 dpi, and 6 dpi (Figure 1F). We observed a significantly higher percentage of neutrophils ($P = 0.02$)
118 and pro-inflammatory monocytes ($P = 0.02$) pre-infection in obese mice compared to lean mice
119 (Figure 1F). No differences were observed for other tested cell types. At 2 dpi, obese mice had a
120 higher percentage of neutrophils ($P = 0.02$) and lower pro-inflammatory monocytes ($P = 0.005$)
121 than lean mice (Figure 1F). B cells trended toward a higher percentage in obese compared to lean
122 mice ($P = 0.09$) (Figure 1F). There were no differences in any tested cell types between lean and
123 obese MAYV-infected groups at 6 dpi (Figure 1F). We also performed flow cytometry on footpad
124 immune cells isolated from lean and obese MAYV-infected mice at peak footpad swelling. There
125 was no difference observed in the proportions of neutrophils, macrophages, and CD8⁺ T cells
126 (Figure 1G). However, a significantly higher percentage of CD4⁺ T cells was seen in obese infected
127 mice footpads. These data suggest that obese mice have slightly altered immune cell populations
128 following alphavirus infection.

129

130 We next performed RT-qPCR on RNA isolated from footpads from MAYV-infected lean and
131 obese mice to evaluate interferon and interferon-stimulated gene (ISG) expression. We observed
132 no statistical difference in IFN- α , IFN- β , and IFN- γ expression between lean and obese groups.
133 Interestingly, ISGs such as Rsad-2, GBP-2, IL-6, IFIT-3b, and MX-1 had significantly higher
134 expression in MAYV-infected lean compared to obese mice (Figure 1H). Moreover, there was a
135 trend toward higher expression of IFIT-1, IFIT-2, STAT-1, IFIT-204, IRF-1, and CXCL-10 in lean
136 infected footpads than obese footpads (Figure S2). Overall, these data suggest that lean mice have
137 a more robust antiviral response to arthritogenic alphavirus infection despite similar levels of IFNs.



138

139 **Figure 1. Clinical severity and immune cell profiling following arthritogenic alphavirus**
 140 **infection in lean and obese mice.** C57BL/6J mice were fed a 10% fat (lean) or 60% fat (obese)
 141 diet for 18-20 weeks. Mice were infected with 10⁴ PFU of MAYV strain TRVL 4675 through
 142 injection of both hind footpads.

143 (A-B) Weight and footpad swelling were measured daily. Data are presented as the percent of
 144 baseline body weight (A) and footpad width (B) (two experiments, n = 9-10). Data were analyzed
 145 by two-way ANOVA with Tukey's correction compared to the lean infected group. The error bars
 146 represent the standard deviation, bars indicate mean values, and asterisks indicate statistical
 147 difference; *p<0.05, **p<0.005, ***p<0.001.

148 **(C-D)** At seven days post-infection, the right hind footpad was collected and fixed. The fixed
149 tissues were then sectioned and stained with hematoxylin and eosin (two experiments, n=10) **(C)**;
150 areas with pronounced infiltrates are indicated by arrows. Images were captured at 20X; scale
151 bar=400 μm . **(D)** An independent anatomic pathologist scored the tissues in a blinded manner.
152 Data were analyzed using multiple unpaired t-tests with the Holm-Sidak correction for multiple
153 comparisons. The error bars represent the standard deviation, bars indicate mean values, and
154 asterisks indicate statistical difference; * $p < 0.05$.

155 **(E)** Multiplex Luminex cytokine assay comparison between pre-infection and 2 days post infection
156 in lean and obese mice. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$. See Figure S1 for the
157 expression of other cytokines.


158 **(F)** Dot graphs present the frequency of B cells ($\text{CD45}^+\text{CD19}^+$), neutrophils
159 ($\text{CD45}^+\text{CD11b}^+\text{Ly6G}^+\text{Ly6C}^+$), anti-inflammatory monocytes ($\text{CD45}^+\text{CD11b}^+\text{Ly6G}^-\text{Ly6C}^{\text{low}}$),
160 pro-inflammatory monocytes ($\text{CD45}^+\text{CD11b}^+\text{Ly6G}^-\text{Ly6C}^{\text{high}}$), CD4^+ T cells ($\text{CD45}^+\text{CD3}^+\text{CD4}^+$),
161 and CD8^+ T cells ($\text{CD45}^+\text{CD3}^+\text{CD4}^+$) at pre-infection, 2, and 6 dpi in the blood of lean and obese
162 MAYV-infected animals detected by flow cytometry. Data were analyzed using multiple unpaired
163 t-tests with the Holm-Sidak correction for multiple comparisons. The error bars represent the
164 standard deviation, bars indicate mean values, and asterisks indicate statistical difference, (one
165 experiment, n = 4-5), * $p < 0.05$.

166 **(G)** Dot graphs present the frequency of neutrophils ($\text{CD45}^+\text{CD11b}^+\text{Ly6G}^+\text{Ly6C}^+$), macrophages
167 ($\text{CD45}^+\text{CD11b}^+\text{F4/80}^+$), CD4^+ T cells ($\text{CD45}^+\text{CD3}^+\text{CD4}^+$), and CD8^+ T cells ($\text{CD45}^+\text{CD3}^+\text{CD4}^+$)
168 at the time of peak swelling in the footpads detected by flow cytometry. Data were analyzed using
169 unpaired t-tests with Welch's correction. The error bars represent the standard deviation, bars
170 indicate mean values, and asterisks indicate statistical difference, * $p < 0.05$.

171 **(H)** RNA was extracted from footpads of MAYV-infected lean and obese mice at 6 dpi and
172 subjected to RT-qPCR. See Fig S2 for the expression of other genes. Data were analyzed using
173 unpaired t-tests with Welch's correction. The error bars represent the standard deviation, bars
174 indicate mean values, and asterisks indicate statistical difference, ** $p < 0.01$.

175 To interrogate the impact of arthritogenic alphavirus on immune cell population dynamics and
176 functionality more thoroughly, we next performed scRNA-seq on immune cells from the blood
177 and footpads from MAYV-infected lean and obese mice. We isolated CD45⁺ cells at two time
178 points, representing the peak of viremia (2 dpi) and footpad swelling (7 dpi); a graphical workflow
179 of the experiment is presented in Figure 2A. For each time point, cells from mock- and MAYV-
180 infected mice were integrated separately from lean and obese mice, visualized as uniform manifold
181 approximation and projection (UMAP) plots, and clustered based on conserved marker genes. As
182 a result, we identified 9-12 cell clusters per group at 2 dpi and 11-16 cell clusters per group at 7
183 dpi in blood samples (Figure S3 and S4). Clusters were then annotated based on the expression of
184 immune cell-specific genes (Figure 2B-C). As expected, a comparison of mock-infected lean and
185 obese mice revealed that immune cell populations remained unchanged between 2 and 7 dpi in the
186 blood (Figures 2D and 2F). In contrast, we observed a considerable shift in B cells, monocytes,
187 neutrophils, T cells, and eosinophils between 2 and 7 dpi in blood samples of MAYV-infected lean
188 and obese mice compared to mock-infected controls (Figure 2E and 2G). In lean MAYV-infected
189 mice, B cells, neutrophils, and T cells increased from 2 dpi to 7 dpi, whereas monocytes and
190 eosinophils were reduced (Figure 2D-E). Similar changes were also observed in B cells and
191 monocytes from obese MAYV-infected mouse blood from 2 to 7 dpi (Figure 2F-G). Overall, these
192 data highlight the considerable impact of MAYV infection on immune cell population dynamics
193 during disease progression in lean and obese hosts.

194 **A**




195


196 **B**

197


198 C




199




D



E



F



G



200

201 **Figure 2. Single cell transcriptomics of immune cell dynamics following arthritogenic**
202 **alphavirus infection in lean and obese mice.** C57BL/6J mice were fed a 10% fat (lean) or 60%
203 fat (obese) diet for 18-20 weeks. Mice were infected with 10⁴ PFU of MAYV strain TRVL 4675

204 through injection of both hind footpads. Blood immune cells were collected at 2 and 7 dpi and
205 processed for scRNA-seq. See Figure S3 for the graphical workflow of experiment.

206 **A. Graphical workflow of scRNA-sequencing.** Mice were inoculated with MAYV or viral
207 diluent, and blood and footpads were collected. Then, leukocytes were isolated, and CD45⁺ cells
208 were purified through positive selection. Libraries were prepared for scRNA-seq, which was
209 followed by data analysis.

210 **(B-C)** Uniform Manifold Approximation and Projection (UMAP) showing integrated datasets
211 from blood at 2 dpi **(B)** and 7 dpi **(C)** of mock- and MAYV-infected lean and obese mice. See also
212 Figures S4 and S5 for the cell clusters identified in each group.

213 **(D-G)** The proportion of each cell type was identified by scRNA-seq of blood at 2dpi and 7dpi
214 from lean **(D-E)** and obese **(F-G)** mock and MAYV-infected groups.

215


216 **Single-cell analysis of early MAYV infection reveals aberrant activation of inflammatory**
217 **monocytes and reduction of B and T cell populations in lean and obese mice**

218 To interrogate peripheral blood immune cell dynamics early during infection at peak viremia, we
219 analyzed differences in the proportion and gene expression profiles of blood immune populations
220 at 2 dpi. MAYV infection caused a significant drop in B cells in both lean (64.08% mock and
221 27.94% infected) and obese (69.43% mock and 36.57% infected) mice (Figure 3A). We also
222 observed a modest decrease in T cells in lean (15.74% mock and 11.93% infected) and obese
223 (9.34% mock and 9.60% infected) groups. In contrast, monocytes increased ~4.8-fold in lean
224 (7.96% mock and 38.24% infected) and ~4-fold in obese (8.6% mock and 34.43% infected) mice
225 in response to MAYV infection. Interestingly, a small population of basophils (1.29%) and stromal
226 cells (2.11%) were detected in MAYV-infected obese mice, which were not detected in the
227 MAYV-infected lean group (Figure 3A). It was previously shown that a subset of adipose-
228 associated stromal cells express CD45, possibly explaining their presence in the blood of obese
229 mice³³.

230

231 Next, we identified differentially expressed genes (DEGs) between mock- and MAYV-infected
232 blood immune cell populations from lean and obese mice at 2 dpi (Figure 3B-C). For each cell
233 population, up- and down-regulated genes in infected mice were used to identify significant
234 overlaps with curated immune cell and pathway gene signatures. B cells and monocytes from
235 infected mice were enriched for signatures indicative of response to type I and type II IFN,
236 consistent with an acute response to virus exposure (Figure 3B). In addition, both B cells and
237 monocyte populations were enriched for IL1 cytokine, MHC Class I, and pattern recognition
238 receptor gene signatures. B cells from lean mice had a more robust enrichment of MHC Class I
239 genes; furthermore, these cells had unique downregulation of genes in N-linked glycosylation and
240 anti-proliferation pathways. N-linked glycosylation has been linked to B cell maturity³⁴.
241 Monocytes from infected mice also exhibited increased expression of M1 macrophage genes and
242 decreased expression of genes involved in antigen presentation as compared to mock infection
243 (Figure 3C). Overall, gene set enrichment was similar between lean and obese mice at 2 dpi. Thus,
244 the initial response to arthritogenic alphavirus infection is characterized by an intense IFN
245 response, B cell lymphopenia, and an increase in M1-like monocytes in both lean and obese mice.
246


247 **A**



248

249 **B**

C



250

251 **Figure 3. scRNA-seq during peak viremia reveals aberrant activation of inflammatory**
252 **monocytes and reduction of B and T cell populations in lean and obese mice in response to**
253 **MAYV infection.**

254 (A) Pie charts show the proportion of immune cells identified in lean and obese mock- and MAYV-
255 infected animals at 2 dpi with scRNA-seq.

256 (B-C) Dot plots depict the differential expression of genes in B cells (B) and monocytes (C) in
257 lean and obese animals. Color change shows the p value difference in log10 compared to mock
258 group and dot size present the odds ratio difference associated with virus infection. UP: increased
259 expression in infected group, DOWN: decreased expression in infected group.

260


261 **Early abnormalities in blood immune cell populations are largely resolved later during**
262 **MAYV infection**

263 We next evaluated the peripheral immune cell transcriptome at 7 dpi, when significant differences
264 in weight loss were observed between MAYV-infected lean and obese mice (Figure 1A). The
265 decrease in B cells in virus-infected mice observed at 2 dpi was largely restored at 7 dpi (Figure
266 4A). The increased proportion of monocytes at 2 dpi was no longer present at the 7 dpi. The
267 proportions of other immune cell populations at 7 dpi in the blood were comparable between lean
268 and obese mice (Figure 4A).

269


270 Interestingly, changes in gene expression between lean and obese mice were more apparent at this
 271 later time point than at 2 dpi in both B cells and monocytes. B cell from infected lean mice showed
 272 enriched expression of type I and II IFN response genes and IL-21 signaling that was not observed
 273 in B cells from obese mice (Figure 4B). Similarly, we observed upregulation of IFN stimulated
 274 genes along with enriched signatures of phagocytosis, glycolysis, and signatures for both M1- and
 275 M2c-like macrophages in infected lean monocytes (Figure 4C). Enrichment for M2c-related genes
 276 at this later time point may indicate a shift towards a more anti-inflammatory state, consistent with
 277 reduced weight loss in lean mice (Figure 1A). In monocytes from infected obese mice, the enriched
 278 gene signatures were similar to those observed in lean animals; however, the magnitude of
 279 enrichment was reduced (Figure 4C). Thus, the immune response to infection at 7 dpi appears to
 280 be reduced in obese mice.

281 **A**



282


283 **B**



284

285 **Figure 4. Resolution of blood abnormalities in immune cell populations late in infection.**

C



286 (A) Pie charts show the proportion of immune cells identified in the blood of lean and obese mock-
287 and MAYV-infected mice at 7 dpi with scRNA-seq.

288 (B-C) Dot plots depict the differential expression of genes in B cells (B) and monocytes (C) from
289 lean and obese mice. Color change shows the p-value difference in log₁₀ compared to mock group
290 and dot size represents the odds ratio difference due to virus infection. UP: increased expression
291 in virus infected group, DOWN: decreased expression in virus infected group.

292

293 **Single-cell profiling of footpad immune cells during MAYV infection at the time of peak** 294 **footpad swelling**

295 To explore individual immune cell transcriptomes during peak footpad swelling, we collected
296 footpads from lean and obese mock- and MAYV-infected mice at 7 dpi, isolated leukocytes and
297 performed scRNA-seq. The UMAP of annotated cell type clusters showed an appreciable
298 difference in macrophage and B cell clusters in response to virus infection (Figure 5A).
299 Macrophages comprised 54.94% and 59.36% of total immune cells in lean and obese MAYV-
300 infected animal footpads, respectively (Figure 5B). In contrast, macrophages comprised only
301 27.38% and 25.45% of immune cells in mock-infected lean and obese mice, respectively.
302 Neutrophils and B cells were reduced in response to infection, whereas monocytes, dendritic cells,
303 and T/NKT cells were increased compared to mock-infected groups in both lean and obese
304 MAYV-infected animals (Figure 5B).

305

306 **Macrophages from obese mice have a unique phenotype**


307

308 Macrophages are critical in arthritogenic alphavirus disease development³⁵. We observed a
309 significant increase in macrophages in footpads from lean and obese mice following MAYV
310 infection (Figure 5B). Thus, we compared macrophage transcriptional signatures in mock- and
311 MAYV-infected mice. MAYV infection induced similar transcriptional changes in macrophages
312 for both lean and obese mice, including enrichment of type I and II IFN response genes, M1-like
313 macrophage, and MHC Class I signatures and downregulation of M2-like macrophage signatures


314 (Figure 5C). However, the IFN-stimulated gene signature, pattern-recognition receptor, IFNK, and
315 IFNB1 gene signatures were more highly enriched in lean than obese mice (Figure 5C). Several
316 pathways were enriched in macrophages from lean but not obese mice including mRNA
317 processing, immunoproteasome, phagocytosis, and endosome and vesicles (Figure 5C).
318 Necroptosis-related pathways were only upregulated in obese macrophages.

319

320



321



322

323 **Figure 5. Assessment of footpad immune cells during MAYV infection at the time of peak**
 324 **footpad swelling.**

325 (A) UMAP presents the cell clusters detected in footpads at 7 dpi in MAYV-infected lean and
 326 obese animals.

327 (B) Pie charts show the proportion of immune cell clusters identified in lean and obese mock- and
 328 MAYV-infected animal footpads.

329 (C) Dot plots depict the differential expression of genes in lean and obese macrophages. Color
 330 change shows the p value difference in log10 compared to mock group and dot size represents the
 331 odds ratio difference due to virus infection. UP: increased expression in virus infected group,
 332 DOWN: decreased expression in virus infected group.

333

334 **Unique transcriptional signatures define the dominant macrophage populations in the**
335 **footpads of lean and obese mice during MAYV infection**

336 We next evaluated specific subsets of macrophages in the footpads of lean and obese mice. Each
337 subset was annotated based on transcriptional overlaps with previously defined macrophage
338 populations from the ImmGen database³⁶. We identified 5 macrophage subsets in lean mock- and
339 MAYV-infected footpads: MF.103-11B+SALM3, MF.103-11B+, MF.103CLOSER,
340 MF.F480HI.GATA6KO, and MFIO5.II+480LO (Figure 6A, Table 1). Whereas the frequency of
341 4/5 of the macrophage subsets was reduced in MAYV- vs. mock-infected animals, the
342 MFIO5.II+480LO subset increased from 39.15% in mock to 58.25% in MAYV-infected mice.
343 Eight distinct macrophage subclusters were detected in mock- and MAYV-infected obese mice:
344 MF.103-11B+, MF.103-11B+24-, MF.103CLOSER, MF.F480HI.CTRL,
345 MF.F480HI.GATA6KO, MF.RP, MFIO5.II-480HI, and MFIO5.II+480INT (Figure 6A, Table 2).
346 Similar to lean mice, 6/8 macrophage populations were reduced in MAYV- vs. mock-infected
347 obese mice; however, MFIO5.II+480INT (mock 47.37%; infected 70.15%) increased in response
348 to infection (Table 2). The dominant macrophage subset was MFIO5.II+480LO and
349 MFIO5.II+480INT in lean and obese mice, respectively (Table 1 and 2). This shift from F480^{lo}
350 macrophages in lean mice to F480^{int} in obese mice suggests a less activated macrophage population
351 in obese animals (Figure 6A, Table 1 and 2).

352 To test this hypothesis, we analyzed the transcriptomes of lean MFIO5.II+480LO
353 (CSF1R⁺SiglecF⁻F4/80^{LOW}MHCII^{high}) and obese MFIO5.II+480INT (CSF1R⁺SiglecF⁻
354 F4/80^{INT}MHCII^{high}) macrophage populations. We observed that the lean mice macrophage
355 subset was enriched for TNF-induced genes, mRNA processing, immunoproteasome, glycolysis,
356 endosome and vesicle, anti-proliferation, and anti-apoptosis gene signatures, and expressed a
357 robust IFN response signature, which was not observed in the obese macrophage subset (Figure
358 6B). Moreover, N-linked glycosylation, RAS superfamily, lipid metabolism, and integrin
359 pathways were uniquely downregulated in the lean macrophage subset. In contrast, the necroptosis
360 signature was uniquely enriched in the obese macrophage population.

361

362 **Table 1: Macrophage subsets identified in lean mock- and MAYV-infected animal footpads**

Subset Annotation	Lean mock cells (%)	Lean MAYV-infected cells (%)	ImmGen Depositor Description
MF.103-11B+SALM3	648 (32.99%)	786 (27.03%)	Tissue: Small Intestine Flow Markers: CD11c ^{hi} CD103 ⁻ CD11b ⁺ Conditions: Day 3 p.i. with <i>S. typhimurium</i>
MF.103-11B+	87 (4.43%)	72 (2.48%)	Tissue: Small Intestine (lamina propria) Flow Markers: CD11c ^{hi} CD103 ⁻ CD11b ⁺
MF.103CLOSER	339 (17.26%)	309 (10.63%)	Tissue: Small Intestine Flow Markers: CD11c ^{lo} CD103 ⁻ CD11b ⁺
MF.F480HI.GATA6KO	121 (6.16%)	47 (1.62%)	Tissue: Peritoneal cavity Flow Markers: F480 ^{hi} ICAM2 ^{hi} CD11b ^{hi} Conditions: Gata6-KO background
MFIO5.II+480LO	769 (39.15%)	1694 (58.25%)	Tissue: Peritoneal cavity Flow Markers: CD115 (CSF1R)⁺ F480^{lo} SiglecF⁻ MHC-II⁺ Conditions: Thio stimulated

363


364 **Table 2: Macrophage subsets identified in obese mock- and MAYV-infected animal footpads**

Subset Annotation	Obese mock cells (%)	Obese MAYV-infected cells (%)	ImmGen Depositor Description
MF.103-11B+	252 (12.49%)	101 (3.86%)	Tissue: Small Intestine (lamina propria) Flow Markers: CD11c ^{hi} CD103 ⁻ CD11b ⁺
MF.103-11B+24-	207 (10.26%)	169 (6.46%)	Tissue: Lung

			Flow Markers: CD103 ⁻ CD11b ⁺ CD24 ⁻ CD11c ⁺ MHC-II ⁺
MF.103CLOSER	142 (7.04%)	188 (7.19%)	Tissue: Small Intestine Flow Markers: CD11c ^{lo} CD103 ⁻ CD11b ⁺
MF.F480HI.CTRL	18 (0.89%)	33 (1.26%)	Tissue: Peritoneal cavity Flow Markers: F480 ^{hi} ICAM2 ^{hi} CD11b ^{hi}
MF.F480HI.GATA6KO	72 (3.57%)	55 (2.10%)	Tissue: Peritoneal cavity Flow Markers: F480 ^{hi} ICAM2 ^{hi} CD11b ^{hi} Conditions: Gata6-KO background
MF.RP	168 (8.33%)	99 (3.78%)	Tissue: Spleen Flow Markers: F480 ^{hi} CD11b ^{lo} Cd11c ⁻
MFIO5.II-480HI	203 (10.06%)	136 (5.20%)	Tissue: Peritoneal cavity Flow Markers: CD115 (CSF1R) ⁺ F480 ^{hi} SiglecF ⁻ MHC-II ⁺ Conditions: Thio stimulated
MFIO5.II+480INT	956 (47.37%)	1835 (70.15%)	Tissue: Peritoneal cavity Flow Markers: CD115 (CSF1R)⁺ F480^{int} SiglecF⁻ MHC-II⁺ Conditions: Thio stimulated


365

366 **A**



367

368 **B**



369

370

371 **Figure 6. Dynamic shifts in macrophage populations in lean and obese mice during MAYV**
 372 **infection.**

373 Macrophage populations identified in mock and MAYV-infected lean and obese animal footpads
 374 were further analyzed to explore the different subclusters of macrophages raised in response to
 375 MAYV infection and their transcriptional profiles.

376 (A) Macrophage subclusters detected in lean and obese mock- and MAYV-infected animal
 377 footpads at 7 dpi.

378 (B) Lean macrophage subset $CSF1R^+SiglecF^+F4/80^{LOW}MHCII^{high}$ and obese macrophage subset
 379 $CSF1R^+SiglecF^+F4/80^{INT}MHCII^{high}$ transcriptional profiles detected in MAYV-infected lean and
 380 obese animals compared to mock groups. Color change shows the p-value difference in log10
 381 compared to the mock group, and dot size represents the odds ratio difference due to virus
 382 infection. UP: increased expression in virus infected group, DOWN: decreased expression in virus
 383 infected group.

384

385 Discussion

386 In 2022, more than 800 million people were considered obese (BMI > 30) worldwide¹⁰, and these
387 numbers are continuing to rise. This is concerning given the health risks associated with the
388 development of obesity and the higher risk of severe disease following infection with different
389 viruses, including arthritogenic alphaviruses^{8,37}. Arthritogenic alphavirus infection induces
390 footpad swelling, myositis, and bone loss in mouse models, similar to human disease^{11,21-23}. Here,
391 we confirmed that obesity leads to worse disease outcomes following arthritogenic alphavirus
392 infection, including increased weight loss and worse tissue inflammation in obese compared to
393 lean mice. Toward understanding the mechanisms underlying these differences, we performed a
394 comprehensive profiling of immune cell phenotypes at various stages of arthritogenic alphavirus
395 disease development in lean and obese mice using scRNA-seq. We observed large shifts in
396 immune cell populations in the blood and footpads of lean and obese mice infected with MAYV.
397 Infection was associated with significant enrichment of genes in known antiviral signaling
398 pathways, along with shifts in antigen presentation, cytokine signaling, and cell death-related
399 genes. In the footpad, we detected lower expression of antiviral gene signatures across most cell
400 types in obese compared to lean mice. Furthermore, we identified a unique CSF1R⁺SiglecF⁻
401 F4/80^{lo}MHCII^{high} macrophage subset in lean mice with enhanced expression of IFN response
402 genes that was not found in obese mice and may account for the diminished pathogenic
403 consequences of MAYV infection in lean mice.

404 We inoculated lean and obese mice with MAYV and found that obese animals developed more
405 severe disease in line with our previous reports showing that infection with CHIKV, MAYV, or
406 RRV led to worse disease outcomes in obese mice¹¹. To evaluate immune cell dynamics during
407 MAYV infection, we carried out scRNAseq at two time points: at 2 dpi, peak viremia³⁸, and 7 dpi,
408 peak footpad swelling. At 2 dpi, we observed a significant drop in B cells and an increase in
409 monocytes in lean and obese mice. A similar trend was observed in previous reports of CHIKV-
410 infected human blood cells²⁵. It has been reported that type I IFN-dependent signaling leads to
411 early suppression of humoral responses when virus-infected B cells are eliminated by
412 inflammatory monocytes³⁹ and CD8 T cells⁴⁰. Type I IFN-related gene pathways were
413 significantly upregulated in monocytes, and it has been reported that blocking type I IFN can result
414 in restoration of the B cell response to the virus during acute infection⁴¹. A direct role of B cells in

415 mediating the resolution of arthritogenic alphavirus disease has also been reported^{42,43}. CHIKV
416 infection in B cell-deficient mice led to persistent infection in the joint, and disease resolution was
417 dependent on antibody-mediated neutralizing activity, cellular cytotoxicity, and complement
418 activation^{43,44}. CHIKV infection in human B cells has been shown in human patient blood cells²⁵
419 and *in vitro* experiments⁴⁵. Interestingly, our B cell transcriptomic data showed that MHC class I
420 signaling genes were highly upregulated in B cells from both lean and obese hosts at 2 dpi, possibly
421 indicative of viral presentation by infected B cells to cytotoxic T cells. The potential relationship
422 between a decrease in B cells and the development of more severe disease should be explored in
423 future studies.

424 Blood monocytes increased significantly in response to infection in both lean and obese mice at 2
425 dpi. Recently, it was reported that Ly6C⁺ monocytes facilitate alphavirus infection at the initial
426 infection site, which promotes more rapid spread into circulation⁴⁶. Furthermore, monocyte
427 recruitment to the draining lymph nodes during CHIKV infection impairs virus-specific B cell
428 responses by virtue of their ability to produce nitric oxide⁴⁷. The substantial reduction in B cells,
429 along with a concomitant rise in monocytes following infection should be explored in future
430 studies.

431 Arthritogenic alphavirus infection in mice produces significant weight loss and footpad swelling
432 at 7 dpi¹¹. We collected blood and footpad immune cells at 7 dpi to determine the effect of infection
433 on immune cell populations during later stages of infection. Most of the cell populations recovered
434 in infected lean and obese mouse blood returned to baseline levels. While we observed only minor
435 differences in immune cell percentages between infected lean and obese animals, changes in gene
436 expression were more apparent at 7 dpi compared to 2 dpi. B cells from lean mice showed enriched
437 expression of type I and II IFN signature genes, IFNG, IFNB1, IFNA2 response genes, and IL-21
438 signaling. B cells from obese mice showed enrichment of genes associated with IFNB1 exposure
439 but none of the other antiviral signaling gene sets and the IL-21 pathway remained unchanged.
440 Higher expression of MHC II-related genes in lean B cells is likely indicative of their role as
441 antigen-presenting cells^{48,49}. Enrichment of IL-21 signaling may explain the higher proliferation
442 and activation of B cells at 7 dpi in lean compared to obese mice, which is predominately mediated
443 through IL-21⁵⁰. Furthermore, we observed upregulation of IFN-associated signaling pathways
444 along with enriched signatures of mRNA processing, endocytosis, and M2c-like gene sets in

445 monocytes from lean compared to obese mice. Enrichment for M2c related genes at this later time
446 point may indicate a shift towards a more anti-inflammatory state in lean mice^{51,52}. Worsened
447 systemic disease outcomes in obese mice could be explained by the dampened expression of type
448 I and II signature genes, IFNG, IFNB1, and IFNA2 response signatures in blood B cells and
449 monocytes.

450 We observed significantly greater footpad swelling and tissue damage in obese compared to lean
451 mice. During alphavirus infection, chemokines attract monocytes and other immune cells to the
452 site of infection⁵³⁻⁵⁷. The monocytes differentiate into macrophages in infected tissues and secrete
453 proinflammatory cytokines such as TNF, IL-6, IL-1 β , and type I IFNs^{45,58-60}. Arthritogenic
454 alphaviruses replicate in monocytes and tissue resident macrophages and may contribute to chronic
455 disease^{35,45,61,62}. scRNA-seq revealed a considerable increase in macrophages and T/NKT cells at
456 7 dpi in the footpads of lean and obese mice. In contrast, B cells dropped significantly in response
457 to infection. Flow cytometric validation also revealed that CD4⁺ T cells were significantly higher
458 in obese compared to lean mice following infection. Previous data shows that CD4⁺ T cells
459 contribute to the development of pathological damage during arthritogenic alphavirus
460 infection^{63,64}, suggesting these cells may contribute to worse tissue damage observed in obese
461 mice.

462
463 Interestingly, M2c, M2a, and M2 macrophage gene expression was significantly reduced in
464 MAYV-infected lean and obese footpad macrophages, which may highlight the loss of anti-
465 inflammatory mediators⁶⁵ during peak footpad swelling. However, IFN stimulated gene signatures
466 were more highly enriched in lean macrophages. IFN response genes are involved in viral sensing
467 and mediating antiviral, immunomodulatory, and antiproliferative effects^{66,67}; thus, the reduced
468 expression in obese host suggests an impaired immune response to MAYV infection. Consistent
469 with this, we previously observed higher virus replication in the footpad of obese mice at peak
470 footpad swelling compared to lean mice¹¹. Several IFN response genes with important roles in
471 viral response were uniquely enriched in macrophages from lean infected mice. Similarly, mRNA
472 processing genes activated in lean macrophages are involved in higher synthesis, modification,
473 mRNA splicing, polyadenylation, and expression of ISGs^{68,69}. The immunoproteasome plays a
474 role in antigen processing and presentation⁷⁰ and genes involved in the transcription of

475 immunoproteasome subunits may increase antigenic peptide generation for MHC I presentation
476 and regulation of immune responses in macrophages^{71,72}. Phagocytosis and endosome and vesicle
477 related genes encode proteins that support macrophage functions to engulf cellular debris and help
478 in clearance of virus infected cells and control of virus replication⁷³⁻⁸¹. The enrichment of these
479 pathways in lean hosts suggests a superior response to virus infection, which may result in better
480 control of virus replication and subsequent disease. In contrast, the unique upregulation of
481 necroptosis-related genes in obese macrophages may contribute to the increase tissue damage
482 observed. Its selective upregulation in obese macrophages suggests a potential link between
483 obesity-related metabolic dysregulation and inflammatory cell death processes, which requires
484 further investigation.

485 We also carried out macrophage subset analysis and found two main subclusters: MFIO5.II+480^{LO}
486 and MFIO5.II+480^{INT} in lean and obese mice, respectively. F4/80 is a cell surface marker for
487 murine macrophages, which is expressed on resident tissue macrophages and is associated with
488 maturation status^{74,75}. Previous studies highlight that F4/80 expression is decreased in activated
489 macrophages as they engulf viral particles and virus infected cells, and process viral proteins to
490 present through MHC-II receptors⁷⁶⁻⁷⁸. Transcriptomic analysis of lean CSF1R⁺SiglecF⁻
491 F4/80^{LOW}MHCII^{high} and obese CSF1R⁺SiglecF⁻F4/80^{INT}MHCII^{high} macrophage populations
492 showed that the lean macrophage subset was enriched not only in IFN response genes, but also in
493 TNF-induced genes, mRNA processing, immunoproteasome, glycolysis, endosome and vesicle,
494 anti-proliferation, and anti-apoptosis gene sets, that were not observed in obese macrophage
495 subset. The upregulation of these pathways is indicative of a inferior macrophage response in obese
496 infected mice that provides a plausible mechanism for increased tissue inflammation and footpad
497 swelling in response to MAYV infection in obese as compared to lean hosts.

498 **Limitations**

499 Our study has several limitations: (1) We used only MAYV for scRNA-seq studies, (2) performed
500 positive selection for CD45 cells and (3) tested footpads at only a single timepoint. Thus, we could
501 not assess the differences in response at different timepoints or the effects on most non-immune
502 cells. Furthermore, we could not perform a comprehensive comparison between arthritogenic
503 alphaviruses. We used MAYV since it is a BSL2 virus and replicates better in mice than CHIKV;

504 however, future studies should provide a more comprehensive comparison between viruses at
505 several timepoints following infection, including during the chronic stage.

506 **Summary:**

507 Our analysis provides a detailed profiling, at the single cell level, of the lean and obese host
508 immune response to arthritogenic alphavirus infection. These studies enhance our understanding
509 of the impact of obesity on immune cell dynamics during viral infection. This work provides
510 multiple targets for therapeutic development, which could prove vital for combating arthritogenic
511 alphavirus disease. The described macrophage subsets and related pathways can be studied further
512 to understand the immunopathogenesis of arthritogenic alphavirus disease and to select targets for
513 therapeutic development. Overall, this study highlights that obesity alters immune cell functional
514 dynamics response to arthritogenic alphavirus infection, which is associated with worse disease
515 outcomes.

516 **Acknowledgments**

517 We are grateful to Andria Doty, Colleen Palmateer, and Jason Monroe for assistance in scRNA-
518 seq sample preparation and analysis. We also thank Melissa Makris for assisting with flow
519 cytometry analysis. This work was funded by the NIH grant R21AI153919-01 awarded to J.W.-L.
520 The graphical abstract and figures were created using BioRender (<https://biorender.com>).

521 **Author contributions**

522 M.H. and J.W.-L. have prepared the experiment plan and wrote the manuscript. M.H. and M.S.H
523 performed experiments. A.D. and P.L. analyzed scRNA-seq data and assisted with manuscript
524 preparation. S.C.-O. analyzed histopathology.

525 **Declaration of interests**

526 The authors declare no competing interests.

527 **Supplementary figure legends**

528 **Supplementary figure 1. Cytokine expression in before and after MAYV infection in lean**
529 **and obese mice.** Mice were bled prior to or 2 days post-MAYV infection and cytokines were
530 measured by multiplex Luminex assay. Comparisons were made using unpaired t tests; *p<0.05,
531 **p<0.01, ***p<0.001, ****p<0.0001.

532
533 **Supplementary figure 2. Antiviral gene expression in lean and obese MAYV infected mice**
534 **footpads.**

535 C57BL/6J lean and obese mice were infected with 10⁴ PFU of MAYV strain TRVL 4675 in each
536 hind footpad and footpads were collected at 7 days post-inoculation. RNA was extracted and
537 subjected to RT-qPCR. Data were normalized to GAPDH and analyzed using unpaired t-tests with
538 Welch's correction. The error bars represent the standard deviation and bars indicate mean values.

539
540 **Supplementary figure 3. Blood immune cell clusters detected at 2 dpi from mock- and**
541 **MAYV-infected lean and obese mice.**

542
543 **Supplementary figure 4.**

544 **Blood immune cell clusters detected at 7 dpi from mock- and MAYV-infected lean and obese**
545 **mice.**

546
547 **Supplementary table 1. List of RT-qPCR primers used to assess gene expression.**

548
549 **Lead contact**

550 Further information and requests for resources and reagents should be directed to and will be
551 fulfilled by the lead contact, James Weger-Lucarelli: weger@vt.edu.

552
553 **Materials availability**

554 This study did not generate new unique reagents.

555

556 **STAR Methods**

557 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Purified rat anti-mouse CD16/CD32 antibody 1/100	BD Biosciences	Cat. No 553142
Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
PerCP/Cyanine5.5 anti-mouse/human CD11b antibody 1/200	BioLegend	AB_893233 (Cat. No. 101227)
Alexa fluor 700 anti-mouse CD45 antibody 1/200	BioLegend	AB_493714 (Cat. No. 103127)
APC anti-mouse Ly-6G antibody 1/100	BioLegend	AB_2227348 (Cat. No. 127614)
PE anti-mouse CD3 antibody 1/100	BioLegend	AB_312663 (Cat. No. 100206)
PerCP/Cyanine5.5 anti-mouse CD4 antibody 1/100	BioLegend	AB_2563023 (Cat. No. 116012)
FITC anti-mouse CD8a antibody 1/200	BioLegend	AB_312745 (Cat. No. 100706)
Brilliant violet 421 anti-mouse F4/80 1/100	BioLegend	AB_10901171 (Cat. No. 123131)
Brilliant violet 421 anti-mouse NK1.1 1/100	BioLegend	AB_2562561 (Cat. No. 108741)
PE anti-mouse Ly-6C antibody 1/400	BioLegend	AB_1186133 (Cat. No. 128007)

APC anti-mouse CD19 1/400	BioLegend	AB_2629839 (Cat. No. 152410)
PE anti-mouse CD119 (IFN-gamma receptor 1) 1/100	Thermo Fischer Scientific	AB_2572673 Cat. No. 12-1191-82
Chemicals		
Collagenase I	Worthington Biochemical Corporation	Cat. No. LS004196
DNase I	Worthington Biochemical Corporation	Cat. No. LS006333
RPMI 1640	Genesee scientific	Cat. No. 25-506N
PBS	Genesee scientific	Ref. No. 25-507B
Heat inactivated fetal bovine serum	R&D systems	Cat. No. S11150H
Bovine serum albumin (BSA)	Thermo Fisher Scientific	Cat. No. FERB14
16% formaldehyde solution (w/v)	Thermo Fisher Scientific	Ref. No. 28908
Zombie aqua fixable viability kit	BioLegend	Cat. No. 423101
1X RBC lysis buffer	Thermo Fisher Scientific	Cat. No. 00-4333-57
Mono-Poly medium	MP biomedical	Cat. No. 091698049
IC fixation/permeabilizati on diluent	eBioscience	Cat. No. 00-5223-56
1X permeabilization Buffer	eBioscience	Cat. No. 00-5223-56
SUPERase•In	Thermo Fisher Scientific	AM2694
Evercode cell fixation V2 kit	Parse Biosciences	ECF2001
Evercode whole transcriptome - up to 48 samples and 100k	Parse Biosciences	EC-W01030

cells/nuclei per experiment		
Other reagents and equipment		
Isoflurane (FLURISO)	Vet one	NDC 13985-528-60
0.5 ml insulin syringe	BD	Ref. No.329461
5 ml polycarbonate tubes	Genesee Scientific	Cat. No. 24-285
15 ml Conical tubes	Genesee Scientific	Cat. No. 28-103
50 ml tubes	Genesee Scientific	Cat. No. 28-106
Advanced cell strainers (70 μ m)	Genesee Scientific	Cat. No. 25-376
PrimeFlow 96 well plates (V bottom)	Thermo Fisher Scientific	Ref. No. 44-17005-46
Ultracomp ebeads	Thermo Fisher Scientific	Cat. No. 01-2222-42
Trypan blue stain 0.4%	Thermo Fisher Scientific	Ref. No. 15250-061
Hausser Scientific Bright-line counting chamber	Thermo Fisher Scientific	Cat. No. 02-671-51B
Evos 5000 imaging system	Thermo Fisher Scientific	Cat. No. AMF5000
Heraeus multifuge x3R	Thermo Fisher Scientific	Ref. No. 7500-4516
Incubator	Shel Lab	Model No. SC06AD
EasySep Mouse CD45 Positive Selection Kit	STEMCELL Technologies	Cat. No. 18945
FACSAria Fusion Flow cytometer	BD Biosciences	
Benchtop shaker Model 55S	Thermo Fisher Scientific	SER. No. 07M1102MS
Glass beads (3mm)	Thermo Fisher Scientific	Cat. No. 11.312A
Low-fat diet with 10% kcal fat	New Brunswick, NJ,	Ref. No. D12450K
High-fat diet with 10% kcal fat	New Brunswick, NJ,	Ref. No. D12492
EasyEight EasySep magnet	STEMCELL Technologies	Cat. No. 18103
Viruses		

Infectious-clone derived Mayaro virus (MAYV)	Chuong et al. 2019 ⁵	Strain: TRVL 4675
Experimental model		
C57BL/6J	The Jackson Laboratory	Strain: C57BL/6J, Male (000664)
Software		
BioRender	Created with BioRender.com	
FlowJo™ v10	BD Biosciences	

558

559 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

560 **Animals and Ethics**

561 We purchased wild-type (WT) C57BL/6J male mice from The Jackson Laboratory. Virus
562 infections were performed in mice anesthetized with isoflurane inhalation and all efforts were
563 made to minimize animal suffering. All experiments were performed with the approval of Virginia
564 Tech's Institutional Animal Care & Use Committee (IACUC) under protocol number 24-060.

565 **Cell lines**

566 Vero cells were obtained from American Type Culture Collection and cultured at 37 °C in
567 Dulbecco's Modified Eagle Medium (DMEM) supplemented with 5% fetal bovine serum (FBS),
568 1% penicillin/streptomycin, and 25mM HEPES in 5% CO₂ incubator.

569 **Viruses**

570 MAYV strain TRVL 4675 was produced from an infectious clone that we previously described³⁸.
571 The MAYV stock was propagated on Vero cells, and supernatants were harvested at 72 h post
572 infection, titrated by plaque assay on Vero cells and stored in aliquots at -80 °C.

573 **Mouse experiments**

574 C57BL/6N mice were housed in groups of five per cage and maintained at ambient temperature
575 with ad libitum supply of food and water. All diets used for the study were obtained from Research
576 Diets (New Brunswick, NJ, USA). In all studies, male mice were used and fed on a low-fat diet
577 with 10% kcal fat and on a high-fat diet with 60% kcal fat. Throughout the manuscript, we refer
578 to the groups as lean (low-fat diet) or obese (high-fat diet). The mice were kept on these diets for
579 18–20 weeks before infections, and the same diets were continued until the end of the experiment.
580 Mice were inoculated with 10^4 PFU of MAYV in a volume of 50 μ l RPMI-1640 media through
581 subcutaneous injections in both hind feet^{11,21}. Virus dilutions were made in RPMI-1640 media
582 supplemented with 10 mM HEPES and 1% FBS. All mouse experiments were performed under
583 ABSL 2/3 conditions. Mice were weighed daily following infection and footpad swelling was
584 measured daily using a digital caliper. Blood was collected from the submandibular vein with a 5
585 mm lancet (Goldenrod) into a purple top microtainer tube (Fisher Scientific) for immune cell
586 isolation. Virus titers were measured by plaque assay using Vero cells.

587 **Tissue processing and H&E staining**

588 At 7 dpi, animals were euthanized, and footpads were collected and fixed in 4% formalin for 48 h.
589 After fixation, footpads were decalcified in 10% EDTA solution at 4 °C for 2 weeks. The Virginia
590 Tech Animal Laboratory Services (VITALS) performed paraffin embedding, sectioning, and
591 staining with hematoxylin and eosin, and a board-certified anatomic pathologist read the slides.

592

593 **Luminex assay**

594 We quantified cytokines levels in the serum at pre- and post-infection from lean and obese animals
595 using the mouse Luminex XL cytokine assay (bio-technique) according to the manufacturer's
596 instructions. The standard curve was generated using the optical density values of the standards,
597 which were used to calculate the cytokine levels in each sample.

598 **Isolation of blood and footpad immune cells using Mono-Poly medium**

599 Blood was collected at 2 dpi (peak viremia) and 7 dpi (severe disease symptoms), and footpads at
600 7 dpi when animals developed peak footpad swelling. We isolated total immune cells using Mono-
601 Poly (MP) medium from blood and footpads. The detailed protocol for mouse footpad digestion,
602 leukocyte isolation, purification using CD45+ selection kit was previously described⁷⁹. For blood

603 cell isolation, an equal amount of blood was pooled from five animals. Then, we layered blood
604 onto the MP medium (1:1 MP medium: blood ratio, place tube at a slight vertical angle and slowly
605 add blood). Centrifuge at 300 x g for 30 minutes in a swinging bucket rotor at room temperature
606 (20-25 °C). Collect cell layers between RBC's and plasma to isolate mononuclear and
607 polymorphonuclear cells and add to a 15 mL conical tube containing 10 mL cold RPMI media
608 supplemented with 10% FBS. Centrifuge at 500 x g for 10 minutes at 4 °C. Resuspend cell pellets
609 in 1 mL RPMI media and proceed for CD45+ purification by following step by step protocol ⁷⁹.
610 For scRNA-seq, we pooled cells from five mice into a single sample, however, we isolated blood
611 and footpad immune cells from each animal and processed separately for flow cytometry.

612

613 **Flow cytometry**

614 Single cell suspensions isolated from lean and obese mice blood and footpads were washed with
615 phosphate buffered saline (PBS) and resuspended in 100 µL Zombie aqua dye solution (1:400
616 prepared in PBS) and incubated at room temperature for 15-30 minutes. 200 µL flow cytometry
617 staining (FACS) buffer (PBS containing 2% FBS) was added and centrifuged for 5 min at 4° C.
618 The resulting cells were resuspended in FACS buffer with 0.5 mg/mL rat anti-mouse CD16/CD32
619 Fc block and incubated for 15 min on ice to block Fc receptors. Combined antibody solution
620 prepared in FACS buffer with fluorophore-conjugated antibodies presented in key resources table.
621 100 µL antibody cocktail was added to the single cell suspension, mixed, and incubated for 30 min
622 on ice. Cells were washed with FACS buffer twice and 100 µL 4% formalin were added to fix
623 cells. After 15 min incubation at room temperature, cells were washed with FACS buffer,
624 resuspended in 100-200 µL PBS and covered with aluminum foil and proceeded for analysis.
625 Single color controls were run with Ultracomp ebeads. The stained cells were analyzed using the
626 FACSAria Fusion Flow cytometer (BD Biosciences).

627

628 **RNA extraction and reverse transcription-quantitative polymerase chain reaction (RT- 629 qPCR) from blood and immune cells**

630

631 Footpads was collected in TRIzol reagent (ThermoFisher) and RNA was extracted according to
632 manufacturer's protocol and store at -80 C until use. RT-qPCR was performed using the NEB
633 Luna Universal One-Step RT-qPCR kit with SYBR-Green reagent (NEB, MA, USA). Primers

634 were ordered from Integrated DNA Technologies (IDT, Iowa, USA) and their sequence
635 information is presented in Table S1. The reaction conditions were 55°C for 10 min for reverse
636 transcription, 95°C for 1 min for initial denaturation and polymerase activation, 95°C for 10
637 seconds for denaturation, and 60°C for 30 seconds for annealing/extension by 45 cycles. Relative
638 gene expression was determined by normalizing with GAPDH gene followed by the two delta-
639 delta Ct ($2^{-\Delta\Delta Ct}$) method of relative quantification.

640

641 **Single cell suspension preparation for single cell RNA sequencing**

642 We fixed CD45+ cells using Evercode cell fixation V2 kit (ECF2001, Parse Biosciences) by
643 following standard fixation protocol provided and detailed step by step protocol has been published
644 previously ⁷⁹. The fixed cells were preserved at -80 °C. Then we sent samples on dry ice from
645 Virginia Tech to the University of Michigan for library preparation and sequencing.

646

647 **Library preparation, single cell RNA sequencing and data analysis**

648 We used Evercode's whole transcriptome kit (EC-W01030, Parse Biosciences) for library
649 preparation and single cell RNA sequencing according to the manufacturer's instructions. Briefly,
650 we loaded 8333 fixed cells from each blood and footpad samples for three rounds of barcoding
651 followed by lysis to isolate barcoded cDNA and prepare sub libraries. These sub libraries were
652 sequenced on an Illumina Novaseq sequencer and generated 30-60 thousand reads per cell. The
653 sequenced data was processed by using Parse Biosciences processing pipeline (v0.9.6p). We
654 aligned sequencing reads to the GRCm38 mouse genome with default settings to demultiplex
655 samples. Briefly, each of the twelve sub libraries was processed individually using the command
656 split-pipe -mode all, and the output was combined by using split-pipe -mode combine.

657

658 Downstream processing of output count, gene/feature, and barcode matrices was performed with
659 R/BioConductor package Seurat (v4.0.2) at default settings unless otherwise noted. Quality control
660 analysis was done to filter for high quality cells and cells with less than 150 or more than 7,500
661 detected unique genes, > 40,000 unique molecular identifiers, and >15% mitochondrial reads were
662 excluded from analysis (all thresholds were set using empirical distributions). Doublet
663 discrimination was performed on filtered data using DoubletFinder (v 2.0.3) and doublets were
664 excluded from downstream analysis. Filtered datasets were divided into Seurat objects

665 corresponding to each sample (lean mock, lean MAYV-infected, obese mock, and obese MAYV-
666 infected) and count normalization and variance stabilization was done for each sample using the
667 SCTransform function. Integrated data analysis was carried out using the most highly variable
668 shared genes to find analogous populations and enable direct comparison of differential gene
669 expression when cell cohorts. Cells were clustered with Seurat using the top 15 principal
670 components (PCs) as determined by the elbow method with a cluster resolution of 0.8 for separate
671 cell cohort analysis and 0.4 resolution for integrated analysis. For visualizing clusters, the Uniform
672 Manifold Approximation and Projection (UMAP) method was used. Cluster markers were
673 identified with FindAllMarkers function (log-transformed fold-change threshold of 0.5 for
674 separate cohort clusters and 0.25 for integrated clusters). Wilcoxon rank-sum tests were performed
675 to determine DEGs between lean and obese mock and MAYV-infected integrated clusters using
676 the FindMarkers function. DEGs with $p < 0.05$ were considered statistically significant.
677

678 **Single Cell cluster annotation**

679 Single-cell clusters were annotated based on cluster marker gene enrichment with predefined
680 immune cell and pathway gene sets as previously described⁸⁰. Curated gene sets were generated
681 from information available in literature, Mouse Genome Informatics (MGI) gene ontology (GO)
682 terms, and immune cell-specific expression collected from the Immunological Genome Project
683 Consortium (ImmGen). Two-sided Fisher's Exact Test in R [`fisher.test()`] was used to determine
684 the statistical differences in cluster marker gene enrichment with curated gene sets. Enrichments
685 with $p < 0.05$ were considered statistically significant.

686

687 **Footpad macrophage sub clustering**

688 Lean and obese mice footpad macrophages were selected for sub clustering. Five clusters from
689 lean and eight clusters from obese mice expressing CD11b cell markers were characterized further
690 using Seurat's subset function as described above and reanalyzed similarly to the main dataset,
691 including running the RunPCA, FindAllMarkers function (resolution = 0.5), FindMarkers

692 function, FindClusters, and RunUMAP functions. Ambiguous cells from the subset were removed,
693 and annotations for the remaining clusters were added to the main dataset. Each macrophage subset
694 composition in lean and obese mice was calculated through dividing the number of specific subset
695 cells by the total percentages of each cell subset either in lean or obese host. For each macrophage
696 subset, differential gene expression analysis was performed on the lean infected cells from the lean
697 mock infected, and obese infected cells from the obese mock infected cells. For summary analyses,
698 clusters were grouped as follows: lean hosts; MF.103-11B+SALM3, MF.103-11B+,
699 MF.103CLOSER, MF.F480HI.GATA6KO, MFIO5.II+480LO, and obese host; MF.103-11B+,
700 MF.103-11B+24-, MF.103CLOSER, MF.F480HI.CTRL, MF.F480HI.GATA6KO, MF.RP,
701 MFIO5.II-480HI, MFIO5.II+480INT.

702

703 **Statistical analysis**

704 All statistics were performed using the GraphPad version 9 and data are presented as mean \pm
705 standard deviation. The statistical tests used to analyze data are described in figure legends.

706

707 **References**

- 708 1. Levi, L.I., and Vignuzzi, M. (2019). Arthritogenic Alphaviruses: A Worldwide Emerging
709 Threat? *Microorganisms* 7. 10.3390/microorganisms7050133.
- 710 2. Suhrbier, A., Jaffar-Bandjee, M.C., and Gasque, P. (2012). Arthritogenic alphaviruses--
711 an overview. *Nat Rev Rheumatol* 8, 420-429. 10.1038/nrrheum.2012.64.
- 712 3. Rodríguez-Morales, A.J., Cardona-Ospina, J.A., Fernanda Urbano-Garzón, S., and
713 Sebastian Hurtado-Zapata, J. (2016). Prevalence of Post-Chikungunya Infection Chronic
714 Inflammatory Arthritis: A Systematic Review and Meta-Analysis. *Arthritis Care Res*
715 (Hoboken) 68, 1849-1858. 10.1002/acr.22900.
- 716 4. Zaid, A., Burt, F.J., Liu, X., Poo, Y.S., Zandi, K., Suhrbier, A., Weaver, S.C., Texeira,
717 M.M., and Mahalingam, S. (2021). Arthritogenic alphaviruses: epidemiological and
718 clinical perspective on emerging arboviruses. *Lancet Infect Dis* 21, e123-e133.
719 10.1016/s1473-3099(20)30491-6.
- 720 5. Sissoko, D., Malvy, D., Ezzedine, K., Renault, P., Moschetti, F., Ledrans, M., and Pierre,
721 V. (2009). Post-epidemic Chikungunya disease on Reunion Island: course of rheumatic
722 manifestations and associated factors over a 15-month period. *PLoS Negl Trop Dis* 3,
723 e389. 10.1371/journal.pntd.0000389.
- 724 6. de Souza, W.M., Fumagalli, M.J., de Lima, S.T.S., Parise, P.L., Carvalho, D.C.M.,
725 Hernandez, C., de Jesus, R., Delafiori, J., Candido, D.S., Carregari, V.C., et al. (2024).
726 Pathophysiology of chikungunya virus infection associated with fatal outcomes. *Cell*
727 *Host Microbe*. 10.1016/j.chom.2024.02.011.

- 728 7. Ng, L.F.P., and Rénia, L. (2024). Live-attenuated chikungunya virus vaccine. *Cell* *187*,
729 813-813.e811. 10.1016/j.cell.2024.01.033.
- 730 8. Padmakumar, B., Jayan, J.B., Menon, R., and Kottarathara, A.J. (2010). Clinical profile
731 of chikungunya sequelae, association with obesity and rest during acute phase. *Southeast*
732 *Asian J Trop Med Public Health* *41*, 85-91.
- 733 9. Ward, Z.J., Bleich, S.N., Cradock, A.L., Barrett, J.L., Giles, C.M., Flax, C., Long, M.W.,
734 and Gortmaker, S.L. (2019). Projected U.S. State-Level Prevalence of Adult Obesity and
735 Severe Obesity. *N Engl J Med* *381*, 2440-2450. 10.1056/NEJMsa1909301.
- 736 10. Boutari, C., and Mantzoros, C.S. (2022). A 2022 update on the epidemiology of obesity
737 and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity
738 and dysmetabolism pandemic continues to rage on. *Metabolism* *133*, 155217.
739 10.1016/j.metabol.2022.155217.
- 740 11. Weger-Lucarelli, J., Carrau, L., Levi, L.I., Rezelj, V., Vallet, T., Blanc, H., Boussier, J.,
741 Megrian, D., Coutermarsh-Ott, S., LeRoith, T., and Vignuzzi, M. (2019). Host nutritional
742 status affects alphavirus virulence, transmission, and evolution. *PLoS Pathog* *15*,
743 e1008089. 10.1371/journal.ppat.1008089.
- 744 12. Lee, Y.S., Wollam, J., and Olefsky, J.M. (2018). An Integrated View of
745 Immunometabolism. *Cell* *172*, 22-40. 10.1016/j.cell.2017.12.025.
- 746 13. Lackey, D.E., and Olefsky, J.M. (2016). Regulation of metabolism by the innate immune
747 system. *Nat Rev Endocrinol* *12*, 15-28. 10.1038/nrendo.2015.189.
- 748 14. Battineni, G., Sagaro, G.G., Chintalapudi, N., Amenta, F., Tomassoni, D., and Tayebati,
749 S.K. (2021). Impact of Obesity-Induced Inflammation on Cardiovascular Diseases
750 (CVD). *Int J Mol Sci* *22*. 10.3390/ijms22094798.
- 751 15. Tripathi, S., Christison, A.L., Levy, E., McGravery, J., Tekin, A., Bolliger, D., Kumar,
752 V.K., Bansal, V., Chiotos, K., Gist, K.M., et al. (2021). The Impact of Obesity on Disease
753 Severity and Outcomes Among Hospitalized Children With COVID-19. *Hosp Pediatr* *11*,
754 e297-e316. 10.1542/hpeds.2021-006087.
- 755 16. Alarcon, P.C., Damen, M., Ulanowicz, C.J., Sawada, K., Oates, J.R., Toth, A., Wayland,
756 J.L., Chung, H., Stankiewicz, T.E., Moreno-Fernandez, M.E., et al. (2023). Obesity
757 amplifies influenza virus-driven disease severity in male and female mice. *Mucosal*
758 *Immunol* *16*, 843-858. 10.1016/j.mucimm.2023.09.004.
- 759 17. Geerling, E., Stone, E.T., Steffen, T.L., Hassert, M., Brien, J.D., and Pinto, A.K. (2021).
760 Obesity Enhances Disease Severity in Female Mice Following West Nile Virus Infection.
761 *Front Immunol* *12*, 739025. 10.3389/fimmu.2021.739025.
- 762 18. Kril, V., Aïqui-Reboul-Paviet, O., Briant, L., and Amara, A. (2021). New Insights into
763 Chikungunya Virus Infection and Pathogenesis. *Annu Rev Virol* *8*, 327-347.
764 10.1146/annurev-virology-091919-102021.
- 765 19. Kafai, N.M., Diamond, M.S., and Fox, J.M. (2022). Distinct Cellular Tropism and
766 Immune Responses to Alphavirus Infection. *Annu Rev Immunol* *40*, 615-649.
767 10.1146/annurev-immunol-101220-014952.
- 768 20. Suhrbier, A., and La Linn, M. (2004). Clinical and pathologic aspects of arthritis due to
769 Ross River virus and other alphaviruses. *Curr Opin Rheumatol* *16*, 374-379.
770 10.1097/01.bor.0000130537.76808.26.
- 771 21. Morrison, T.E., Oko, L., Montgomery, S.A., Whitmore, A.C., Lotstein, A.R., Gunn,
772 B.M., Elmore, S.A., and Heise, M.T. (2011). A mouse model of chikungunya virus-

- 773 induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis,
774 myositis, and persistence. *Am J Pathol* 178, 32-40. 10.1016/j.ajpath.2010.11.018.
- 775 22. Santos, F.M., Dias, R.S., de Oliveira, M.D., Costa, I., Fernandes, L.S., Pessoa, C.R., da
776 Matta, S.L.P., Costa, V.V., Souza, D.G., da Silva, C.C., and de Paula, S.O. (2019).
777 Animal model of arthritis and myositis induced by the Mayaro virus. *PLoS Negl Trop*
778 *Dis* 13, e0007375. 10.1371/journal.pntd.0007375.
- 779 23. Morrison, T.E., Whitmore, A.C., Shabman, R.S., Lidbury, B.A., Mahalingam, S., and
780 Heise, M.T. (2006). Characterization of Ross River virus tropism and virus-induced
781 inflammation in a mouse model of viral arthritis and myositis. *J Virol* 80, 737-749.
782 10.1128/jvi.80.2.737-749.2006.
- 783 24. Wilson, J.A., Prow, N.A., Schroder, W.A., Ellis, J.J., Cumming, H.E., Gearing, L.J., Poo,
784 Y.S., Taylor, A., Hertzog, P.J., Di Giullonardo, F., et al. (2017). RNA-Seq analysis of
785 chikungunya virus infection and identification of granzyme A as a major promoter of
786 arthritic inflammation. *PLoS Pathog* 13, e1006155. 10.1371/journal.ppat.1006155.
- 787 25. Michlmayr, D., Pak, T.R., Rahman, A.H., Amir, E.D., Kim, E.Y., Kim-Schulze, S.,
788 Suprun, M., Stewart, M.G., Thomas, G.P., Balmaseda, A., et al. (2018). Comprehensive
789 innate immune profiling of chikungunya virus infection in pediatric cases. *Mol Syst Biol*
790 14, e7862. 10.15252/msb.20177862.
- 791 26. Lim, E.X.Y., Webster, J.A., Rudd, P.A., and Herrero, L.J. (2022). Pathways Activated by
792 Infected and Bystander Chondrocytes in Response to Ross River Virus Infection. *Viruses*
793 15. 10.3390/v15010136.
- 794 27. Olsen, T.K., and Baryawno, N. (2018). Introduction to Single-Cell RNA Sequencing.
795 *Curr Protoc Mol Biol* 122, e57. 10.1002/cpmb.57.
- 796 28. Papalex, E., and Satija, R. (2018). Single-cell RNA sequencing to explore immune cell
797 heterogeneity. *Nat Rev Immunol* 18, 35-45. 10.1038/nri.2017.76.
- 798 29. Cao, J., Packer, J.S., Ramani, V., Cusanovich, D.A., Huynh, C., Daza, R., Qiu, X., Lee,
799 C., Furlan, S.N., Steemers, F.J., et al. (2017). Comprehensive single-cell transcriptional
800 profiling of a multicellular organism. *Science* 357, 661-667. 10.1126/science.aam8940.
- 801 30. Tang, F., Barbacioru, C., Wang, Y., Nordman, E., Lee, C., Xu, N., Wang, X., Bodeau, J.,
802 Tuch, B.B., Siddiqui, A., et al. (2009). mRNA-Seq whole-transcriptome analysis of a
803 single cell. *Nature Methods* 6, 377-382. 10.1038/nmeth.1315.
- 804 31. Stephenson, E., Reynolds, G., Botting, R.A., Calero-Nieto, F.J., Morgan, M.D., Tuong,
805 Z.K., Bach, K., Sungnak, W., Worlock, K.B., Yoshida, M., et al. (2021). Single-cell
806 multi-omics analysis of the immune response in COVID-19. *Nature Medicine* 27, 904-
807 916. 10.1038/s41591-021-01329-2.
- 808 32. Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martínez-Colón, G.J., McKechnie, J.L.,
809 Ivison, G.T., Ranganath, T., Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of
810 the peripheral immune response in patients with severe COVID-19. *Nature Medicine* 26,
811 1070-1076. 10.1038/s41591-020-0944-y.
- 812 33. Nasti, A., Sakai, Y., Seki, A., Buffa, G.B., Komura, T., Mochida, H., Yamato, M.,
813 Yoshida, K., Ho, T.T.B., Takamura, M., et al. (2017). The CD45(+) fraction in murine
814 adipose tissue derived stromal cells harbors immune-inhibitory inflammatory cells. *Eur J*
815 *Immunol* 47, 2163-2174. 10.1002/eji.201646835.
- 816 34. Trzos, S., Link-Lenczowski, P., and Pocheć, E. (2023). The role of N-glycosylation in B-
817 cell biology and IgG activity. The aspects of autoimmunity and anti-inflammatory
818 therapy. *Front Immunol* 14, 1188838. 10.3389/fimmu.2023.1188838.

- 819 35. Gardner, J., Anraku, I., Le, T.T., Larcher, T., Major, L., Roques, P., Schroder, W.A.,
820 Higgs, S., and Suhrbier, A. (2010). Chikungunya virus arthritis in adult wild-type mice. *J*
821 *Virol* *84*, 8021-8032. 10.1128/jvi.02603-09.
- 822 36. Gautier, E.L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., Chow,
823 A., Elpek, K.G., Gordonov, S., et al. (2012). Gene-expression profiles and transcriptional
824 regulatory pathways that underlie the identity and diversity of mouse tissue macrophages.
825 *Nat Immunol* *13*, 1118-1128. 10.1038/ni.2419.
- 826 37. Aghili, S.M.M., Ebrahimpur, M., Arjmand, B., Shadman, Z., Pejman Sani, M., Qorbani,
827 M., Larijani, B., and Payab, M. (2021). Obesity in COVID-19 era, implications for
828 mechanisms, comorbidities, and prognosis: a review and meta-analysis. *Int J Obes (Lond)*
829 *45*, 998-1016. 10.1038/s41366-021-00776-8.
- 830 38. Chuong, C., Bates, T.A., and Weger-Lucarelli, J. (2019). Infectious cDNA clones of two
831 strains of Mayaro virus for studies on viral pathogenesis and vaccine development.
832 *Virology* *535*, 227-231. 10.1016/j.virol.2019.07.013.
- 833 39. Sammicheli, S., Kuka, M., Di Lucia, P., de Oya, N.J., De Giovanni, M., Fioravanti, J.,
834 Cristofani, C., Maganuco, C.G., Fallet, B., Ganzer, L., et al. (2016). Inflammatory
835 monocytes hinder antiviral B cell responses. *Sci Immunol* *1*.
836 10.1126/sciimmunol.aah6789.
- 837 40. Moseman, E.A., Wu, T., de la Torre, J.C., Schwartzberg, P.L., and McGavern, D.B.
838 (2016). Type I interferon suppresses virus-specific B cell responses by modulating
839 CD8(+) T cell differentiation. *Sci Immunol* *1*. 10.1126/sciimmunol.aah3565.
- 840 41. Ng, C.T., Sullivan, B.M., Teijaro, J.R., Lee, A.M., Welch, M., Rice, S., Sheehan, K.C.,
841 Schreiber, R.D., and Oldstone, M.B. (2015). Blockade of interferon Beta, but not
842 interferon alpha, signaling controls persistent viral infection. *Cell Host Microbe* *17*, 653-
843 661. 10.1016/j.chom.2015.04.005.
- 844 42. Lum, F.M., Teo, T.H., Lee, W.W., Kam, Y.W., Rénia, L., and Ng, L.F. (2013). An
845 essential role of antibodies in the control of Chikungunya virus infection. *J Immunol* *190*,
846 6295-6302. 10.4049/jimmunol.1300304.
- 847 43. Hawman, D.W., Fox, J.M., Ashbrook, A.W., May, N.A., Schroeder, K.M.S., Torres,
848 R.M., Crowe, J.E., Jr., Dermody, T.S., Diamond, M.S., and Morrison, T.E. (2016).
849 Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. *Cell*
850 *Rep* *16*, 1326-1338. 10.1016/j.celrep.2016.06.076.
- 851 44. Fox, J.M., and Diamond, M.S. (2016). Immune-Mediated Protection and Pathogenesis of
852 Chikungunya Virus. *J Immunol* *197*, 4210-4218. 10.4049/jimmunol.1601426.
- 853 45. Her, Z., Malleret, B., Chan, M., Ong, E.K., Wong, S.C., Kwek, D.J., Tolou, H., Lin, R.T.,
854 Tambyah, P.A., Rénia, L., and Ng, L.F. (2010). Active infection of human blood
855 monocytes by Chikungunya virus triggers an innate immune response. *J Immunol* *184*,
856 5903-5913. 10.4049/jimmunol.0904181.
- 857 46. Holmes, A.C., Lucas, C.J., Brisse, M.E., Ware, B.C., Hickman, H.D., Morrison, T.E., and
858 Diamond, M.S. (2024). Ly6C(+) monocytes in the skin promote systemic alphavirus
859 dissemination. *Cell Rep* *43*, 113876. 10.1016/j.celrep.2024.113876.
- 860 47. McCarthy, M.K., Reynoso, G.V., Winkler, E.S., Mack, M., Diamond, M.S., Hickman,
861 H.D., and Morrison, T.E. (2020). MyD88-dependent influx of monocytes and neutrophils
862 impairs lymph node B cell responses to chikungunya virus infection via Irf5, Nos2 and
863 Nox2. *PLoS Pathog* *16*, e1008292. 10.1371/journal.ppat.1008292.

- 864 48. Rastogi, I., Jeon, D., Moseman, J.E., Muralidhar, A., Potluri, H.K., and McNeel, D.G.
865 (2022). Role of B cells as antigen presenting cells. *Front Immunol* *13*, 954936.
866 10.3389/fimmu.2022.954936.
- 867 49. Ghosh, D., Jiang, W., Mukhopadhyay, D., and Mellins, E.D. (2021). New insights into B
868 cells as antigen presenting cells. *Curr Opin Immunol* *70*, 129-137.
869 10.1016/j.coi.2021.06.003.
- 870 50. Dvorscek, A.R., McKenzie, C.I., Robinson, M.J., Ding, Z., Pitt, C., O'Donnell, K., Zotos,
871 D., Brink, R., Tarlinton, D.M., and Quast, I. (2022). IL-21 has a critical role in
872 establishing germinal centers by amplifying early B cell proliferation. *EMBO Rep* *23*,
873 e54677. 10.15252/embr.202254677.
- 874 51. Zhou, Y., Yu, X., Chen, H., Sjöberg, S., Roux, J., Zhang, L., Ivoulsou, A.-H., Bensaid,
875 F., Liu, C.-L., and Liu, J. (2015). Leptin deficiency shifts mast cells toward anti-
876 inflammatory actions and protects mice from obesity and diabetes by polarizing M2
877 macrophages. *Cell metabolism* *22*, 1045-1058.
- 878 52. Italiani, P., and Boraschi, D. (2014). From monocytes to M1/M2 macrophages:
879 phenotypical vs. functional differentiation. *Frontiers in immunology* *5*, 514.
- 880 53. Herrero, L.J., Sheng, K.C., Jian, P., Taylor, A., Her, Z., Herring, B.L., Chow, A., Leo,
881 Y.S., Hickey, M.J., Morand, E.F., et al. (2013). Macrophage migration inhibitory factor
882 receptor CD74 mediates alphavirus-induced arthritis and myositis in murine models of
883 alphavirus infection. *Arthritis Rheum* *65*, 2724-2736. 10.1002/art.38090.
- 884 54. Zaid, A., Tharmarajah, K., Mostafavi, H., Freitas, J.R., Sheng, K.C., Foo, S.S., Chen, W.,
885 Vider, J., Liu, X., West, N.P., et al. (2020). Modulation of Monocyte-Driven Myositis in
886 Alphavirus Infection Reveals a Role for CX(3)CR1(+) Macrophages in Tissue Repair.
887 *mBio* *11*. 10.1128/mBio.03353-19.
- 888 55. Lin, T., Geng, T., Harrison, A.G., Yang, D., Vella, A.T., Fikrig, E., and Wang, P. (2020).
889 CXCL10 Signaling Contributes to the Pathogenesis of Arthritogenic Alphaviruses.
890 *Viruses* *12*. 10.3390/v12111252.
- 891 56. Deshmane, S.L., Kremlev, S., Amini, S., and Sawaya, B.E. (2009). Monocyte
892 chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res* *29*, 313-326.
893 10.1089/jir.2008.0027.
- 894 57. Gregory, J.L., Morand, E.F., McKeown, S.J., Ralph, J.A., Hall, P., Yang, Y.H., McColl,
895 S.R., and Hickey, M.J. (2006). Macrophage migration inhibitory factor induces
896 macrophage recruitment via CC chemokine ligand 2. *J Immunol* *177*, 8072-8079.
897 10.4049/jimmunol.177.11.8072.
- 898 58. Lidbury, B.A., Rulli, N.E., Suhrbier, A., Smith, P.N., McColl, S.R., Cunningham, A.L.,
899 Tarkowski, A., van Rooijen, N., Fraser, R.J., and Mahalingam, S. (2008). Macrophage-
900 derived proinflammatory factors contribute to the development of arthritis and myositis
901 after infection with an arthrogenic alphavirus. *J Infect Dis* *197*, 1585-1593.
902 10.1086/587841.
- 903 59. Assunção-Miranda, I., Bozza, M.T., and Da Poian, A.T. (2010). Pro-inflammatory
904 response resulting from sindbis virus infection of human macrophages: implications for
905 the pathogenesis of viral arthritis. *J Med Virol* *82*, 164-174. 10.1002/jmv.21649.
- 906 60. Haist, K.C., Burrack, K.S., Davenport, B.J., and Morrison, T.E. (2017). Inflammatory
907 monocytes mediate control of acute alphavirus infection in mice. *PLoS Pathog* *13*,
908 e1006748. 10.1371/journal.ppat.1006748.

- 909 61. Labadie, K., Larcher, T., Joubert, C., Mannioui, A., Delache, B., Brochard, P., Guigand,
910 L., Dubreil, L., Lebon, P., Verrier, B., et al. (2010). Chikungunya disease in nonhuman
911 primates involves long-term viral persistence in macrophages. *J Clin Invest* *120*, 894-906.
912 10.1172/jci40104.
- 913 62. Felipe, V.L.J., Paula, A.V., and Silvio, U.I. (2020). Chikungunya virus infection induces
914 differential inflammatory and antiviral responses in human monocytes and monocyte-
915 derived macrophages. *Acta Trop* *211*, 105619. 10.1016/j.actatropica.2020.105619.
- 916 63. Hoarau, J.J., Jaffar Bandjee, M.C., Krejbich Trotot, P., Das, T., Li-Pat-Yuen, G., Dassa,
917 B., Denizot, M., Guichard, E., Ribera, A., Henni, T., et al. (2010). Persistent chronic
918 inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust
919 host immune response. *J Immunol* *184*, 5914-5927. 10.4049/jimmunol.0900255.
- 920 64. Teo, T.H., Lum, F.M., Claser, C., Lulla, V., Lulla, A., Merits, A., Rénia, L., and Ng, L.F.
921 (2013). A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice.
922 *J Immunol* *190*, 259-269. 10.4049/jimmunol.1202177.
- 923 65. Atella, M.O., Carvalho, A.S., and Da Poian, A.T. (2023). Role of macrophages in the
924 onset, maintenance, or control of arthritis caused by alphaviruses. *Exp Biol Med*
925 (Maywood) *248*, 2039-2044. 10.1177/15353702231214261.
- 926 66. Schneider, W.M., Chevillotte, M.D., and Rice, C.M. (2014). Interferon-stimulated genes:
927 a complex web of host defenses. *Annu Rev Immunol* *32*, 513-545. 10.1146/annurev-
928 immunol-032713-120231.
- 929 67. Perng, Y.C., and Lenschow, D.J. (2018). ISG15 in antiviral immunity and beyond. *Nat*
930 *Rev Microbiol* *16*, 423-439. 10.1038/s41579-018-0020-5.
- 931 68. Guillemin, A., Kumar, A., Wencker, M., and Ricci, E.P. (2021). Shaping the Innate
932 Immune Response Through Post-Transcriptional Regulation of Gene Expression
933 Mediated by RNA-Binding Proteins. *Front Immunol* *12*, 796012.
934 10.3389/fimmu.2021.796012.
- 935 69. Schott, J., Reitter, S., Philipp, J., Haneke, K., Schäfer, H., and Stoecklin, G. (2014).
936 Translational regulation of specific mRNAs controls feedback inhibition and survival
937 during macrophage activation. *PLoS Genet* *10*, e1004368.
938 10.1371/journal.pgen.1004368.
- 939 70. Rivett, A.J., and Hearn, A.R. (2004). Proteasome function in antigen presentation:
940 immunoproteasome complexes, peptide production, and interactions with viral proteins.
941 *Current Protein and Peptide Science* *5*, 153-161.
- 942 71. Ferrington, D.A., and Gregerson, D.S. (2012). Immunoproteasomes: structure, function,
943 and antigen presentation. *Prog Mol Biol Transl Sci* *109*, 75-112. 10.1016/b978-0-12-
944 397863-9.00003-1.
- 945 72. Haorah, J., Heilman, D., Diekmann, C., Osna, N., Donohue, T.M., Jr., Ghorpade, A., and
946 Persidsky, Y. (2004). Alcohol and HIV decrease proteasome and immunoproteasome
947 function in macrophages: implications for impaired immune function during disease. *Cell*
948 *Immunity* *229*, 139-148. 10.1016/j.cellimm.2004.07.005.
- 949 73. Jutras, I., and Desjardins, M. (2005). Phagocytosis: at the crossroads of innate and
950 adaptive immunity. *Annu Rev Cell Dev Biol* *21*, 511-527.
951 10.1146/annurev.cellbio.20.010403.102755.
- 952 74. Lin, H.H., Faunce, D.E., Stacey, M., Terajewicz, A., Nakamura, T., Zhang-Hoover, J.,
953 Kerley, M., Mucenski, M.L., Gordon, S., and Stein-Streilein, J. (2005). The macrophage

- 954 F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells
955 in peripheral tolerance. *J Exp Med* 201, 1615-1625. 10.1084/jem.20042307.
- 956 75. Dos Anjos Cassado, A. (2017). F4/80 as a Major Macrophage Marker: The Case of the
957 Peritoneum and Spleen. *Results Probl Cell Differ* 62, 161-179. 10.1007/978-3-319-
958 54090-0_7.
- 959 76. Ezekowitz, R.A., Austyn, J., Stahl, P.D., and Gordon, S. (1981). Surface properties of
960 bacillus Calmette-Guérin-activated mouse macrophages. Reduced expression of
961 mannose-specific endocytosis, Fc receptors, and antigen F4/80 accompanies induction of
962 Ia. *J Exp Med* 154, 60-76. 10.1084/jem.154.1.60.
- 963 77. Ezekowitz, R.A., and Gordon, S. (1982). Down-regulation of mannosyl receptor-
964 mediated endocytosis and antigen F4/80 in bacillus Calmette-Guérin-activated mouse
965 macrophages. Role of T lymphocytes and lymphokines. *J Exp Med* 155, 1623-1637.
966 10.1084/jem.155.6.1623.
- 967 78. Nussenzweig, M.C., Steinman, R.M., Unkeless, J.C., Witmer, M.D., Gutchinov, B., and
968 Cohn, Z.A. (1981). Studies of the cell surface of mouse dendritic cells and other
969 leukocytes. *J Exp Med* 154, 168-187. 10.1084/jem.154.1.168.
- 970 79. Hameed, M., Rai, P., Makris, M., and Weger-Lucarelli, J. (2023). Optimized protocol for
971 mouse footpad immune cell isolation for single-cell RNA sequencing and flow
972 cytometry. *STAR Protoc* 4, 102409. 10.1016/j.xpro.2023.102409.
- 973 80. Daamen, A.R., Alajoleen, R.M., Grammer, A.C., Luo, X.M., and Lipsky, P.E. (2023).
974 Single-cell RNA sequencing analysis reveals the heterogeneity of IL-10 producing
975 regulatory B cells in lupus-prone mice. *Front Immunol* 14, 1282770.
976 10.3389/fimmu.2023.1282770.
977